Trials / Completed
CompletedNCT02618928
The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in France
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 735 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to determine the effectiveness of the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) in participants with chronic hepatitis C (CHC) virus in clinical practices across France.
Conditions
Timeline
- Start date
- 2015-12-15
- Primary completion
- 2018-03-29
- Completion
- 2018-03-29
- First posted
- 2015-12-02
- Last updated
- 2019-06-17
- Results posted
- 2019-06-17
Locations
70 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02618928. Inclusion in this directory is not an endorsement.